Perceptive Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$139M Sell
4,423,974
-34,000
-0.8% -$980K 2.72% 9
2025
Q4
$111M Buy
4,457,974
+662,080
+17% +$13.3M 1.97% 13
2025
Q3
$61.6M Sell
3,795,894
-844,055
-18% -$12M 1.78% 19
2025
Q2
$60.8M Sell
4,639,949
-1,907,379
-29% -$27.5M 2.26% 9
2025
Q1
$144M Buy
6,547,328
+3,861,791
+144% +$101M 5.09% 4
2024
Q4
$71.7M Buy
2,685,537
+355,243
+15% +$11.3M 1.98% 13
2024
Q3
$62.2M Buy
2,330,294
+473,877
+26% +$9.43M 1.32% 26
2024
Q2
$33.4M Sell
1,856,417
-463,229
-20% -$8.08M 0.81% 37
2024
Q1
$42.3M Buy
2,319,646
+1,764,091
+318% +$28M 0.74% 45
2023
Q4
$6.08M Buy
+555,555
New +$3.9M 0.14% 72

Other funds holding EWTX

Perceptive Advisors's EWTX Position: Q1 2026 in Review

Perceptive Advisors reduced its Edgewise Therapeutics (EWTX) stake by 0.76% in Q1 2026, selling an estimated $980K and leaving 4,423,974 shares worth $139M. The position accounts for 2.72% of the portfolio, ranked #9.

Perceptive Advisors first reported a position in EWTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $144M in Q1 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Perceptive Advisors held 4,423,974 shares of Edgewise Therapeutics worth $139M as of Q1 2026.
  • Perceptive Advisors sold 34,000 Edgewise Therapeutics shares in Q1 2026, an estimated $980K.
  • Edgewise Therapeutics made up 2.72% of Perceptive Advisors's portfolio in Q1 2026, its #9 holding.
  • Perceptive Advisors first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Perceptive Advisors's Edgewise Therapeutics position peaked at $144M in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.